<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03179449</url>
  </required_header>
  <id_info>
    <org_study_id>PEDSBRNCNS0008</org_study_id>
    <secondary_id>NCI-2017-00959</secondary_id>
    <secondary_id>PEDSBRNCNS0008</secondary_id>
    <secondary_id>P30CA124435</secondary_id>
    <secondary_id>IRB-39245</secondary_id>
    <nct_id>NCT03179449</nct_id>
  </id_info>
  <brief_title>In Vivo Characterization of Macrophages in Pediatric Patients With Malignant Brain Tumors Using Ferumoxytol-enhanced MRI</brief_title>
  <official_title>MR Imaging of Inflammatory Responses in the Central Nervous System With Ferumoxytol-Enhanced MRI (Pediatric Brain Tumor Protocol)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Michael Iv</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot early phase I trial studies how well ferumoxytol-enhanced magnetic resonance
      imaging (MRI) correlates with inflammatory (macrophage) responses in pediatric patients with
      malignant brain tumors. If there is good correlation, ferumoxytol-enhanced MRI can serve as a
      noninvasive imaging biomarker of inflammation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:

      I. To establish the magnetic resonance (MR) imaging signal characteristics of macrophages in
      pediatric patients (&gt;= 2 years old) with newly diagnosed malignant brain tumors using
      ferumoxytol, an ultrasmall superparamagnetic iron oxide (USPIO) particle.

      SECONDARY OBJECTIVES:

      I. To correlate the MRI signal of ferumoxytol uptake in macrophages with the number of
      macrophages in surgical tumor specimen at histopathology.

      OUTLINE:

      Patients receive a single intravenous infusion of ferumoxytol over 15 minutes. After 24
      hours, patients undergo ferumoxytol-enhanced magnetic resonance imaging (MRI). Patients will
      then undergo MRI-localized tissue sampling and tumor resection.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2017</start_date>
  <completion_date type="Anticipated">July 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2019</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Iron concentration measurements</measure>
    <time_frame>Day 1</time_frame>
    <description>Obtain susceptibility measurements and relaxation times (R2, R2*, R2') in patients receiving ferumoxytol.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Macrophages on histopathology</measure>
    <time_frame>Days 2-4</time_frame>
    <description>Determine the number of macrophages in tissue samples at histopathology.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Childhood Brain Neoplasm</condition>
  <arm_group>
    <arm_group_label>Diagnostic (ferumoxytol-enhanced MRI)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects in the experimental arm will have a single intravenous dose of ferumoxytol (5 mg Fe/kg), to be administered 24 hours before the subject undergoes ferumoxytol-enhanced magnetic resonance imaging (MRI). These subjects will subsequently undergo surgery, and tissue analysis of surgically resected samples (specifically the number of iron-containing and non-iron-containing macrophages) will be correlated with imaging features on ferumoxytol-enhanced MRI.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Diagnostic (ferumoxytol-enhanced MRI)</intervention_name>
    <description>Undergo ferumoxytol-enhanced MRI</description>
    <arm_group_label>Diagnostic (ferumoxytol-enhanced MRI)</arm_group_label>
    <other_name>CONTRAST ENHANCED MRI</other_name>
    <other_name>Contrast-enhanced MRI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgery</intervention_name>
    <description>Undergo surgical resection</description>
    <arm_group_label>Diagnostic (ferumoxytol-enhanced MRI)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ferumoxytol</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Diagnostic (ferumoxytol-enhanced MRI)</arm_group_label>
    <other_name>Feraheme</other_name>
    <other_name>FERUMOXYTOL NON-STOICHIOMETRIC MAGNETITE</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Tissue Analysis</intervention_name>
    <description>Correlative analysis for macrophage detection and quantification. This applies for all patients in the experimental arm who undergo ferumoxytol infusion.</description>
    <arm_group_label>Diagnostic (ferumoxytol-enhanced MRI)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Any patient with suspected malignant brain tumor on diagnostic MR imaging who will
             undergo a resection

        Exclusion Criteria:

          -  Informed consent cannot be obtained either from the patient or legal representative

          -  Severe coexisting or terminal systemic disease that may interfere with the conduct of
             the study

          -  Contraindication to MRI (metal implants)

          -  Hemosiderosis/hemochromatosis

          -  Iron overload from any cause (not just hemosiderosis or hemochromatosis), even if
             secondary to frequent blood transfusions, severe chronic hemolysis, excess dietary or
             parenteral iron, or any other etiology

          -  Known hypersensitivity to ferumoxytol or any of its components

          -  Pregnant patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Iv</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paymon Rezaii</last_name>
    <phone>650-743-8336</phone>
    <email>prezaii@stanford.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford University, School of Medicine</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paymon Rezaii</last_name>
      <phone>650-743-8336</phone>
      <email>prezaii@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Iv</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 5, 2017</study_first_submitted>
  <study_first_submitted_qc>June 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 7, 2017</study_first_posted>
  <last_update_submitted>July 14, 2017</last_update_submitted>
  <last_update_submitted_qc>July 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Michael Iv</investigator_full_name>
    <investigator_title>Clinical Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ferrosoferric Oxide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

